AUNP-12 TFA (Synonyms: NP-12 TFA) |
| Catalog No.GC60607 |
AUNP-12 TFA (NP-12 TFA) es un péptido antagonista de la vÍa de seÑalizaciÓn de PD-1, muestra un antagonismo equipotente hacia PD-L1 y PD-L2 en el rescate de la proliferaciÓn de linfocitos y funciones efectoras. AUNP-12 TFA exhibe activaciÓn inmunolÓgica, excelente actividad antitumoral y potencial para un mejor manejo de los eventos adversos relacionados con el sistema inmunolÓgico (irAE).
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].
NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively [1].NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively [1].
[1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *